Slide 1: Stock exchange cover letter for investor presentation
25th January, 2022 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Sc
Slide 2: Investor Presentation Q3FY22
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q3FY22 January 25, 2022
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: Robust momentum across key markets; strong traction in One India and US
Robust momentum across key markets; Strong traction in One- IndiaCLICK TObusiness and US EDIT MASTER TITLE STYLE drive Q3FY22 performance Overall Revenue Overall EBITDA Sustained traction across 6% branded & generic markets; EBITDA Margin Continued strong margin modest contribution of trajectory (Q3
Slide 5: Strong capital structure and robust free cash flow generation
Strong capital structure and robust free cash flow CLICK TO generation EDIT MASTER continues TITLE STYLE in Q3FY22 Net Cash1 / Equity Cash Balances2 (INR Cr) 0.16 4,148 3,750 0.11 Mar'21 Dec'21 Mar'21 Dec'21 ▪ Strong operating profitability and prudent working capital management drives robust free c
Slide 6: Continued portfolio expansion with long-term partnerships and launches
Continued portfolio expansion with long-term partnerships CLICK TO & launches EDIT MASTER across TITLE STYLE our strategic markets ✓ Approval for Lanreotide injection 505 (b)(2) US Generics ✓ Albuterol total market share1 15.9%|Arformoterol total market share1 26.8% ✓ Launched Spirofy®; India's firs
Slide 7: Financial Performance – Q3FY22
Financial Performance – Q3FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,479 Cr 6% YoY EBITDA INR 1,243 Cr │ 22.7% 3% YoY Q3 FY22 (Consolidated) Revenue1 Break-up Actuals API, 3% vs Q3 FY 21 Others, 1% (Rs Cr) International Total Revenue from Markets, 5,479 6% 13% Operations EBITDA 1,243 -3% I
Slide 8: One India: Consistent execution driving growth across businesses
One India (Rx + Gx+ CHL1): Consistent execution driving CLICK growth TO EDIT across MASTER TITLE businesses STYLE in India One India Branded prescription business #3 Overall IPM2 │5.3% market share2 Brands launched in Rs. Cr Q3 Y-o-Y ❖ Market beating growth for the 32 9MFY22 3rd consecutive quarter
Slide 9: Global consumer wellness franchise gaining traction
Global consumer wellness franchise gaining traction CLICK TO EDIT MASTER TITLE STYLE ~8% contribution to overall revenues in 9MFY22; Improving consumer health outcomes Anchor consumer brands in India1 Anchor consumer brands in South Africa 9% #1 #1 35% Pain Relief Category (9MFY22 NRT* (9MFY22 YoY g
Slide 10: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global CLICK TO EDIT MASTER TITLE STYLE Access South Africa2 SAGA: -4% Y-o-Y $ Mn 9 Brands launched in ❖ Market beating growth continues in SA Private Q3FY22 South Africa (SA) private business; market Q3 Y-o-Y tender business performed in-line with e
Slide 11: North America: Continued traction in core formulation portfolio
North America: Continued traction in core formulation CLICKexpands portfolio; TO EDIT MASTER peptideTITLE STYLE portfolio Key Business Highlights North America ❖ Robust momentum in core formulation business; strong traction in respiratory portfolio with YoY growth of 36%2 $ Mn ❖ New approval: Lanreo
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 31st December 2021)
ANDA & NDA1 Portfolio & Pipeline (As on 31st December 2021) CLICK TO EDIT MASTER TITLE STYLE Total ANDAs 167 18 72 257 & NDAs 18 60 8 4 19 81 8 3 1 41 9 5 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet produc
Slide 13: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API $ Mn $ Mn Q3 Y-o-Y Q3 Y-o-Y 100 -2% 98 27 -27% 20 Q3FY21 Q3FY22 Q3FY21 Q3FY22 Key Business Highlights Key Business Highlights ❖ Performance attributed to momentary ❖ Maintained scale supported by strong DTM1 slo
Slide 14: Strong progress on strategic priorities for FY25
In FY22, we delivered strong progress on our strategic CLICK TO EDIT MASTER TITLE STYLE priorities for FY25 FY25 targets YTD FY22 progress Launch & scale-up in Expanding lung leadership globally and maximising value opportunity in Incremental opportunity to respiratory assets Albuterol & US complex
Slide 15: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com